REGIS HEALTHCARE LIMITED (REG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

REG - REGIS HEALTHCARE LIMITED

FNArena Sector : Aged Care & Seniors

Year End: June

GICS Industry Group : Health Care Equipment & Services

Debt/EBITDA: 0.04

Index: ASX300 | ALL-ORDS

Regis Healthcare owns and operates residential aged-care homes across Australia, providing permanent, respite, dementia and palliative care services.

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$6.15 27 Aug 2026	0.040 OPEN $6.21	0.65% HIGH $6.26	1,262,610 LOW $6.00

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$6.15

27 Aug
2026

0.040

OPEN

$6.21

0.65%

HIGH

$6.26

1,262,610

LOW

$6.00

TARGET

$7.517

22.2% upside

Franking for last dividend paid out: 100%

OTHER COMPANIES IN THE SAME SECTOR
EGH . INA . LIC . OCA . RYM . SNZ .

FNARENA'S MARKET CONSENSUS FORECASTS

Title	FY25 Actual	FY26 Actual	FY27 Forecast	FY28 Forecast
EPS (cps)	xxx	18.4	21.8	xxx
DPS (cps)	xxx	0.0	23.1	xxx
EPS Growth	xxx	13.5%	18.2%	xxx
DPS Growth	xxx	N/A	N/A	xxx
PE Ratio	xxx	N/A	28.0	xxx
Dividend Yield	xxx	N/A	3.8%	xxx
Div Pay Ratio(%)	xxx	N/A	106.1%	xxx

Dividend yield today if purchased 3 years ago: 0.00%

Last ex-div: 12/03 - ex-div 9c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2026 FactSet UK Limited. All rights reserved

Title	2021	2022	2023	2024	2025	2026
EPS Basic	xxx	xxx	xxx	xxx	xxx	18.4
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	1,343.6 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	-4.0
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	336.3 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	4.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2021	2022	2023	2024	2025	2026
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-
Return on Assets	xxx	xxx	xxx	xxx	xxx	2.37 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	142.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2021	2022	2023	2024	2025	2026
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	1 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	3 M
Total Debt	xxx	xxx	xxx	xxx	xxx	4 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	695 M
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	174 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2021	2022	2023	2024	2025	2026
Capex	xxx	xxx	xxx	xxx	xxx	142.0 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	10.57 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	1,191 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	102 M
Research & Development	xxx	xxx	xxx	xxx	xxx	-
Investments - Total	xxx	xxx	xxx	xxx	xxx	127 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Macquarie	xx/xx/xxxx	1	xxxxxxxxxx	$xx.xx	xx.xx%	Broker commentary and detailed analysis is available for Full Members Only. Login above or Get a Free Trial
UBS	25/08/2026	3	Neutral	$6.75	9.76%	Regis Healthcare's FY26 EBITDA of $138m was around 2% ahead of UBS' expectations and above guidance, with better staff costs lifting the EBITDA margin to 10.2%, around 30bps ahead of forecasts, while cash flow remained strong. The analyst sees medium-term earnings and cash flow support from the increasing proportion of RAD (refundable accommodation deposit)-paying residents, RAD retention and a 10% price increase across 70% of the portfolio. This is expected to generate an additional $500m of RAD inflows. Near-term risks remain around September's AN-ACC funding decision and the challenging transition to Higher Everyday Living Fees, where Regis is lagging peers in signing up new residents. FY27 EPS forecasts are cut by -4% on higher D&A. Neutral rating retained. Target price slips to $6.75 from $7.00. FORECAST UBS forecasts a full year FY27 dividend of 22.00 cents and EPS of 22.00 cents. UBS forecasts a full year FY28 dividend of 26.00 cents and EPS of 26.00 cents.
Ord Minnett	xx/xx/xxxx	1	xxx	$xx.xx	xx.xx%	Broker commentary and detailed analysis is available for Full Members Only. Login above or Get a Free Trial

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Macquarie

xx/xx/xxxx

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

25/08/2026

Neutral

$6.75

9.76%

Regis Healthcare's FY26 EBITDA of $138m was around 2% ahead of UBS' expectations and above guidance, with better staff costs lifting the EBITDA margin to 10.2%, around 30bps ahead of forecasts, while cash flow remained strong.

The analyst sees medium-term earnings and cash flow support from the increasing proportion of RAD (refundable accommodation deposit)-paying residents, RAD retention and a 10% price increase across 70% of the portfolio.

This is expected to generate an additional $500m of RAD inflows.

Near-term risks remain around September's AN-ACC funding decision and the challenging transition to Higher Everyday Living Fees, where Regis is lagging peers in signing up new residents.

FY27 EPS forecasts are cut by -4% on higher D&A. Neutral rating retained. Target price slips to $6.75 from $7.00.

FORECAST
UBS forecasts a full year FY27 dividend of 22.00 cents and EPS of 22.00 cents.
UBS forecasts a full year FY28 dividend of 26.00 cents and EPS of 26.00 cents.

Ord Minnett

xx/xx/xxxx

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Jarden	25/08/2026	3	Neutral	$7.50	21.95%	Jarden maintains its Neutral recommendation for Regis Healthcare with a target price of $7.50 following a solid FY26 earnings result featuring underlying EBITDA of $138m, which came in 2.2% ahead of consensus expectations. Operating revenues reached $1,350.6m, up 16% compared to the prior corresponding period, while underlying net profit after tax totalled $55.6m. Average occupancy remained robust at 95.8%, and net refundable accommodation deposit inflows reached $250.5m. The broker's estimates indicate that incoming refundable accommodation deposit averages increased 20% year-on-year, with advertised room prices lifted by 10% across a large portion of the portfolio in July and August 2026. The analyst highlights that enhanced net refundable accommodation deposit inflows from higher room pricing are expected to drive future retention revenue, supporting a positive operational outlook.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Jarden

25/08/2026

Neutral

$7.50

21.95%

Jarden maintains its Neutral recommendation for Regis Healthcare with a target price of $7.50 following a solid FY26 earnings result featuring underlying EBITDA of $138m, which came in 2.2% ahead of consensus expectations.

Operating revenues reached $1,350.6m, up 16% compared to the prior corresponding period, while underlying net profit after tax totalled $55.6m.

Average occupancy remained robust at 95.8%, and net refundable accommodation deposit inflows reached $250.5m.

The broker's estimates indicate that incoming refundable accommodation deposit averages increased 20% year-on-year, with advertised room prices lifted by 10% across a large portion of the portfolio in July and August 2026.

The analyst highlights that enhanced net refundable accommodation deposit inflows from higher room pricing are expected to drive future retention revenue, supporting a positive operational outlook.

Access Extra Coverage Research History >

REG STOCK CHART

FNArena News on REG

1	FNArena Corporate Results Monitor – 25-08-2026 Aug 25 2026 - Australia

2	Australian Broker Call Extra Edition – Aug 25, 2026 Aug 25 2026 - Daily Market Reports

3	Next Week At A Glance – 10-14 Aug 2026 Aug 07 2026 - Weekly Reports

4	Rudi’s View: That’s The Way Markets Crumble Aug 06 2026 - Rudi's View

5	Rudi’s View: Pre-August Picks In Resources, Retail & Small Caps Jul 23 2026 - Rudi's View

Latest Aged Care & Seniors News

1	SMSFundamentals: Should You Sell Your Home To Buy Your Nursing ‘Home’? Apr 24 2025 - SMSFundamentals

2	SMSFundamentals: Living Longer? Get Ready To Pay The Price! Jan 31 2025 - SMSFundamentals

3	Treasure Chest: Regis Healthcare Sep 18 2024 - Treasure Chest

4	Treasure Chest: Lifestyle Communities En Vogue Mar 19 2024 - Treasure Chest

5	Lifestyle Communities Enjoying Strong Demand Feb 21 2022 - Small Caps

6	Aged Care Sector: Poised Mar 16 2021 - Australia

7	Pressure Grows On Estia Health Dec 10 2019 - Australia

8	Aveo Group Now A Binary Proposition Jun 26 2019 - Australia

9	Aged Care Moves Into The RC Spotlight Sep 20 2018 - Australia

10	Regis Healthcare In Strong Shape For FY19 Sep 04 2018 - Australia

Dividend Yield Today On Last Actual Payout :	0.00
Estimated Dividend Growth (Average Of Past Three Years)	%
Amount Invested	$
Tell Me The Dividend After This Many Years

	Yield	Yield on investment
This Year
Year 1
Year 2
Year 3
Year 4
Year

Get 2 Weeks free trial

Sign Up

Member Login

REGIS HEALTHCARE LIMITED (REG)
Share Price Analysis and Chart